

We use [cookies](#) to track usage and preferences. [I Understand](#)

Systematic Review

[Open Access](#)

The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review

Christina Greenaway^{1,2}, Manish Pareek³, Claire-Nour Abou Chakra⁴, Moneeza Walji², Iuliia Makarenko², Balqis Alabdulkarim², Catherine Hogan^{1,2}, Ted McConnell², Brittany Scarfo², Robin Christensen^{5,6}, Anh Tran⁷, Nick Rowbotham⁷, Marieke J van der Werf⁸, Teymur Noori⁸, Kevin Pottie⁹, Alberto Matteelli¹⁰, Dominik Zenner^{11,12}, Rachael L. Morton⁷

Affiliations:

¹ Division of Infectious Diseases, Jewish General Hospital, McGill University, Montreal, Canada

² Centre for Clinical Epidemiology of the Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada

³ Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom

⁴ Division of Infectious Diseases, Sherbrooke, Canada

⁵ Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark

⁶ Department of Rheumatology, Odense University Hospital, Denmark

⁷ National Health and Medical Research Council, NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia

⁸ European Centre for Disease Prevention and Control, Stockholm, Sweden

⁹ Bruyere Research Institute, University of Ottawa, Ottawa, Ontario, Canada

¹⁰ Clinic of Infectious and Tropical Diseases, University of Brescia and Brescia Spedali Civili General Hospital, World Health Organization Collaborating Centre for TB/HIV and TB Elimination, Brescia, Italy

¹¹ Respiratory Diseases Department, Centre for Infectious Disease Surveillance and Control (CIDSC), Public Health England, London, United Kingdom

¹² Department of Infection and Population Health, University College London, London, United Kingdom

Correspondence: Christina Greenaway (ca.greenaway@mcgill.ca)

Citation style for this article: Greenaway Christina, Pareek Manish, Abou Chakra Claire-Nour, Walji Moneeza, Makarenko Iuliia, Alabdulkarim Balqis, Hogan Catherine, McConnell Ted, Scarfo Brittany, Christensen Robin, Tran Anh, Rowbotham Nick, van der Werf Marieke J, Noori Teymur, Pottie Kevin, Matteelli Alberto, Zenner Dominik, Morton Rachael L.. The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review. *Euro Surveill.* 2018;23(14):pii=17-00543. <https://doi.org/10.2807/1560-7917.ES.2018.23.14.17-00543>

Received: ; Accepted:

Abstract



Background

Migrants account for a large and growing proportion of tuberculosis (TB) cases in low-incidence countries in the European Union/European Economic Area (EU/EEA) which are primarily due to reactivation of latent TB infection (LTBI). Addressing LTBI among migrants will be critical to achieve TB elimination. **Methods:** We conducted a systematic review to determine effectiveness (performance of diagnostic tests, efficacy of treatment, uptake and completion of screening and

treatment) and a second systematic review on cost-effectiveness of LTBI screening programmes for migrants living in the EU/EEA. **Results:** We identified seven systematic reviews and 16 individual studies that addressed our aims. Tuberculin skin tests and interferon gamma release assays had high sensitivity (79%) but when positive, both tests poorly predicted the development of active TB (incidence rate ratio: 2.07 and 2.40, respectively). Different LTBI treatment regimens had low to moderate efficacy but were equivalent in preventing active TB. Rifampicin-based regimens may be preferred because of lower hepatotoxicity (risk ratio = 0.15) and higher completion rates (82% vs 69%) compared with isoniazid. Only 14.3% of migrants eligible for screening completed treatment because of losses along all steps of the LTBI care cascade. Limited economic analyses suggest that the most cost-effective approach may be targeting young migrants from high TB incidence countries. **Discussion:** The effectiveness of LTBI programmes is limited by the large pool of migrants with LTBI, poorly predictive tests, long treatments and a weak care cascade. Targeted LTBI programmes that ensure high screening uptake and treatment completion will have greatest individual and public health benefit.



This work is licensed under a Creative Commons Attribution 4.0 International License.

Comment has been disabled for this content